Clinical Trials Sponsored by Cytoki Pharma

Total 8371 results

LEO Pharma

Completed

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Actinic Keratosis

United States, Canada
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Actinic Keratosis

United States
ERYtech Pharma

No longer available

Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase (EAP)

Acute Lymphoblastic Leukemia

France
LEO Pharma

Completed

Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions

Actinic Keratosis

United States
pH Pharma

Completed

Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma

Normal Tension Glaucoma

Korea, Republic of
Getz Pharma

Completed

Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients

Chronic Heart Failure
Horus Pharma

Unknown

Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness

Dry Eye
UCB Pharma

Completed

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease (COSPAR II)

Crohn's Disease

United States, Germany, Canada
UCB Pharma

Completed

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

Rheumatoid Arthritis

United States
ERYtech Pharma

Completed

Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma

Pancreatic Adenocarcinoma Metastatic

France
LEO Pharma

Completed

The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo

Impetigo | Secondarily Infected Traumatic Lesions (SITL)

United States
UCB Pharma

Completed

eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam (VERVE)

Epilepsy

United States, Australia, Bulgaria, Denmark, France, Germany, Romania, Spain, Sweden
UCB Pharma

Terminated

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Epilepsy

United States, France, Germany, Spain, Hungary, Italy
UCB Pharma

Completed

An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

Epilepsy

Canada, United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Spain, Sweden
UCB Pharma

Completed

Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.

Epilepsy

Spain, United States, Belgium, Czechia, Mexico, Poland
ERYtech Pharma

Terminated

L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States
Kukje Pharma

Unknown

[KJ-INT-002] BE Study

Gastritis

Korea, Republic of
LEO Pharma

Completed

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

Hand Eczema

Germany
LEO Pharma

Completed

Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer

Venous Thromboembolism

France
LEO Pharma

Completed

Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam

Drug Interaction Potentiation

Germany
UCB Pharma

Completed

An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

Chronic Refractory Neuropathic Pain

Germany
UCB Pharma

Terminated

Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee

Osteoarthritis

Poland, Germany, Romania, Hungary, United Kingdom, Sweden, Czechia
UCB Pharma

Terminated

Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide (VICTOR)

Epilepsy, Partial

Austria, Germany, Spain
UCB Pharma

Completed

An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures

Epilepsy | Generalized Tonic-clonic Seizures

Japan
CleveXel Pharma

Completed

Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease

Idiopathic Parkinson Disease

France
LEO Pharma

Completed

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

Actinic Keratosis

United States
GNT Pharma

Unknown

Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC) (SONIC)

Ischemic Stroke

Korea, Republic of
Insud Pharma

Completed

Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)

Helminthiasis
LEO Pharma

Completed

A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris

Skin and Connective Tissue Diseases

France
LEO Pharma

Completed

Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

Actinic Keratosis (AK)

Germany
LEO Pharma

Completed

A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)

Atopic Dermatitis

Canada, Israel
LEO Pharma

Completed

A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (LP0113-1123)

Skin and Connective Tissue Diseases

France
LEO Pharma

Completed

Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris

Acne Vulgaris

France
Vifor Pharma

Completed

Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Atopic Dermatitis
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

Actinic Keratosis

Germany
UCB Pharma

Completed

UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)

Epilepsy | Pregnancy Complications | Seizures | Birth Defects

United States
LEO Pharma

Completed

A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris

Psoriasis Vulgaris

France
Cardeas Pharma

Completed

Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers

Healthy

United States
LEO Pharma

Completed

Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

Atopic Dermatitis

Germany
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

Actinic Keratosis

Germany
LEO Pharma

Completed

Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%

Actinic Keratosis

Australia, Germany
Innate Pharma

Completed

Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma (REMYKIR)

Multiple Myeloma

France
PLx Pharma

Completed

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

Diabetes Mellitus, Type 2

United States
LEO Pharma

Completed

LEO 29102 Single and Multiple Dose Study by Dermal Application

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
Patara Pharma

Completed

Treatment of Refractory Chronic Cough With PA101

Refractory Chronic Cough

Netherlands, United Kingdom
Cardeas Pharma

Withdrawn

Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization

Pneumonia, Bacterial
Kiadis Pharma

Completed

Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States, Canada, Netherlands, Germany, Belgium, United Kingdom
AM-Pharma

Withdrawn

A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia (SLIC)

Candidaemia

Netherlands

3

Subscribe